Halozyme Therapeutics (HALO) Misses Q4 EPS by 9c, Offers Guidance

Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of ($0.24), $0.09 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $53.7 million versus the consensus estimate of $56.93 million.

GUIDANCE:

Halozyme Therapeutics sees FY2020 EPS of $0.60-$0.75, versus the consensus of $0.58. Halozyme Therapeutics sees FY2020 revenue of $230-245 million, versus the consensus of $220.7 million.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.

You May Also Be Interested In

• Fox upgraded to overweight as Roku deal, ad strength lift outlook
• Calamp Corp. (CAMP) Misses Q2 EPS by 33c
• DeFi Technologies Inc. (DEFT) Reports Q2 Loss of $0.04